报告期内，华润博雅生物坚定践行华润「1246」模式，凭藉「四个重塑」(价值重塑、业务重塑、组织 重塑、精神重塑)，克服复杂多变市场环境带来的困难，引领学术发展，化解历史风险，预期可实现经 营收益同比增长10.00%至25.00%，主要由于收购绿十字香港控股有限公司所致。 格隆汇1月30日丨华润医药(03320.HK)公布华润博雅生物截至2025年12月31日止年度的业绩预告。于 2026年1月30日，华润博雅生物公布其截至2025年12月31日止年度的业绩预告，据此，其公告截至2025 年12月31日止年度归属于华润博雅生物股东的净利润预计介乎约人民币1.05亿元至人民币1.37亿元(上年 同期净利润约人民币3.97亿元)、扣除非经常性损益後归属于华润博雅生物股东的净亏损预计介乎约人 民币750万元至人民币1500万元(上年同期净利润约人民币3.02亿元)(「华润博雅生物业绩预告」)。 ...

Core Viewpoint - China Resources Pharmaceutical (华润医药) announced a significant decline in the net profit of its subsidiary, China Resources Boya Bio (华润博雅生物), for the fiscal year ending December 31, 2025, primarily due to market challenges and the impact of acquisitions [1][2] Group 1: Financial Performance - The net profit attributable to shareholders of China Resources Boya Bio is expected to be approximately RMB 105 million to RMB 136.5 million, a substantial decrease from the previous year's net profit of approximately RMB 397 million [1] - The expected net loss attributable to shareholders, after excluding non-recurring gains and losses, is projected to be between RMB 7.5 million and RMB 15 million, compared to a net profit of approximately RMB 302 million in the previous year [1] - The anticipated impact of non-recurring gains and losses on net profit is about RMB 120 million, influenced by government subsidies, asset sales, and wealth management income [2] Group 2: Business Challenges - The decline in net profit is largely attributed to the underperformance of aesthetic medical products, specifically hyaluronic acid, distributed by Anhui Greenke Pharmaceutical Co., which is a wholly-owned subsidiary of Green Cross Hong Kong Holdings, acquired by China Resources Boya Bio in November 2024 [2] - The company faced significant impairment losses on intangible assets and goodwill totaling approximately RMB 300 million due to the market downturn [2] - The blood products business of China Resources Boya Bio has been adversely affected by intensified market competition, expanded centralized procurement, and reforms in medical insurance, leading to a decrease in clinical prescriptions and demand, as well as a decline in gross margin year-on-year [2] Group 3: Strategic Initiatives - During the reporting period, China Resources Boya Bio is committed to implementing the "1246" model and focusing on "four remolds" (value remolding, business remolding, organizational remolding, and spiritual remolding) to navigate the complex market environment and drive academic development [1]

Financial Performance Expectations - The company expects a net profit of approximately ¥10,500 million for 2025, representing a decline of 65.62% to 73.55% compared to the previous year[4] - Revenue is projected to be between ¥190,839 million and ¥216,863 million, indicating a year-on-year increase of 10.00% to 25.00%[4] - Non-recurring gains and losses are estimated to impact net profit by approximately ¥1.2 billion, compared to ¥0.95 billion in the same period last year[6] - The financial data in the earnings forecast has not been audited by external auditors[5] - The specific financial figures will be detailed in the company's 2025 annual report[7] Acquisition Impact - The decline in net profit is primarily due to a ¥3 billion impairment loss on intangible assets and goodwill related to the acquisition of Green Cross Hong Kong Holdings Limited[6] - The acquisition of Green Cross Hong Kong Holdings Limited is expected to contribute to the revenue growth[5] Market Challenges - The blood products business has faced challenges due to increased market competition and regulatory changes, leading to a decrease in clinical prescription volumes[6] - The company is implementing a "1246" model and focusing on "four remakes" to navigate the complex market environment[5] Investor Guidance - Investors are advised to make cautious decisions and be aware of investment risks[7]

华润博雅生物制药集团股份有限公司 关于全资子公司获得《药品补充申请批准通知书》的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 近日，华润博雅生物制药集团股份有限公司（以下简称"公司"）之全资子 公司绿十字香港控股有限公司的全资子公司绿十字（中国）生物制品有限公司（以 下简称"绿十字（中国）"）收到国家药品监督管理局核准签发的 3 个规格静注 人免疫球蛋白（pH4）《药品补充申请批准通知书》（通知书编号：2026B00463、 2026B00465、2026B00466）。现将有关情况公告如下： 证券代码：300294 证券简称：博雅生物 公告编号：2026-004 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 此次申请事项符合药品注册的有关要求，批准本品补充申请。 一、药品的基本情况 （一）《药品补充申请批准通知书》（通知书编号：2026B00463） 药品名称：静注人免疫球蛋白（pH4） 剂型：注射剂 规格：1.25g/瓶（5%，25ml） 受理号：CYSB2400097 药品注册标准编号：YBS00372009 上市许可持有人名称： ...

Market Overview - The biopharmaceutical sector experienced a decline of 1.3% on January 29, with Hualan Vaccine leading the drop [1] - The Shanghai Composite Index closed at 4157.98, up 0.16%, while the Shenzhen Component Index closed at 14300.08, down 0.3% [1] Individual Stock Performance - Weigao Bio (002880) saw a closing price of 30.07, with an increase of 4.59% and a trading volume of 88,100 shares, totaling a transaction value of 266 million yuan [1] - Changchun High-tech (000661) closed at 98.30, up 0.92%, with a trading volume of 64,700 shares and a transaction value of 629 million yuan [1] - Other notable performers include Boya Bio (300294) and Zhifei Biological (300122), both with a closing price increase of 0.92% and 0.73% respectively [1] Declining Stocks - Hualan Bio (301207) reported a significant decline of 9.05%, closing at 22.62, with a trading volume of 300,600 shares and a transaction value of 689 million yuan [2] - Junshi Biosciences (688180) fell by 6.02%, closing at 36.82, with a trading volume of 266,100 shares and a transaction value of 1 billion yuan [2] - Other stocks such as Jinkang (688670) and Bohui Innovation (300318) also experienced declines of 5.81% and 4.95% respectively [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 866 million yuan from institutional investors, while retail investors contributed a net inflow of 682 million yuan [2] - Notable net inflows from retail investors were observed in stocks like Shanghai Laishi (002252) and Weigao Bio (002880) [3] - Conversely, stocks such as Zhixiang Quantai (688443) and Weigao Bio (002880) experienced significant net outflows from institutional and speculative investors [3]

而如何为其提供专业化的投后赋能，更决定了项目是否能带来可持续性的回报。目前高特佳已搭建了聚焦"深度行业研究+丰富生态资源+成熟资本运作"为 特色的专业投后赋能平台，辐射战略咨询、产业对接、人才引进、品牌公关、融资服务等多个模块，助力生态圈企业价值提升。 展望未来，高特佳投资将继续坚守医疗健康单一赛道，深化专业壁垒。无论时代如何演进，生老病死的自然规律不会因技术飞跃而改变，健康始终是人类最 本质、最永恒的追求。在这一不可动摇的需求基石上，生物医药产业展现出穿越周期的强大韧性。从精准靶向的创新疗法，到普惠可及的预防保障，生物医 药产业所彰显出不可替代的战略价值，证明该赛道存在永续的投资机遇。高特佳投资将持续以金融资本的力量，发现并培育具有全球竞争力的创新企业，推 动中国生物医药产业的高质量发展，为投资人创造长期价值，为健康中国建设贡献专业力量。 高特佳投资是中国私募股权投资领域为数不多、长期坚持聚焦于单一赛道的专业投资机构。2001年高特佳投资在深圳成立，率先在业内提出"主题行业投 资"的投资模式，专注医疗健康产业投资。历经25年深耕，构建起跨越周期的产业认知体系与独特的价值投资框架。 高特佳投资资产管理规模超2 ...

Group 1 - The core point of the article is that Boya Bio (300294) reported the number of shareholders, including those with credit accounts, as 30,593 as of January 20, 2026 [1]

Group 1 - The core viewpoint of the article is that the stock price of Boya Bio (300294) in the secondary market is influenced by macroeconomic conditions, market policies, and investor risk preferences [1] Group 2 - The company advises investors to refer to its regular reports for information regarding its operational performance [1]

Group 1 - The biopharmaceutical sector increased by 0.19% on January 21, with Nearshore Protein leading the gains [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] - Key stocks in the biopharmaceutical sector showed significant price increases, with Nearshore Protein rising by 6.37% to a closing price of 48.76 [1] Group 2 - The biopharmaceutical sector experienced a net inflow of 77.04 million yuan from institutional investors, while retail investors saw a net outflow of 284 million yuan [2] - Major stocks like Watson Bio and Ganli Pharmaceutical attracted significant institutional investment, with net inflows of 64.45 million yuan and 55.25 million yuan, respectively [3] - Retail investors showed a negative trend in several stocks, with Watson Bio and Ganli Pharmaceutical experiencing net outflows of 33.30 million yuan and 39.14 million yuan, respectively [3]

Group 1 - The core point of the article is the recent personnel changes at Tian Tan Biological Products, a subsidiary of China National Pharmaceutical Group, which aims to adapt to market changes and strengthen its position in the blood products industry [2][8] - Yang Huichuan resigned as chairman but remains as a board member and general manager, while Liang Hongjun has been elected as the new chairman [2][3] - Under Yang's leadership, the company saw steady revenue growth in 2023 and 2024, with revenues of 5.18 billion and 6.032 billion yuan respectively, and net profits of 1.11 billion and 1.549 billion yuan, marking increases of 25.99% and 39.58% [2][5] Group 2 - The blood products industry in China has experienced increasing performance differentiation and intensified market competition, prompting Tian Tan Biological's strategic personnel adjustments [2][6] - Liang Hongjun's appointment comes at a critical time as the company faces profit pressure, with a reported net profit decline of 22.16% in the first three quarters of 2025 [4][5] - The industry has seen a narrowing growth rate, with some companies like Hualan Biological and Boya Biological experiencing significant revenue declines, while others like Tian Tan Biological and Shanghai Lai Si have shown revenue growth [6][7] Group 3 - The blood products sector is undergoing consolidation, with fewer than 30 operational companies in China, making license resources scarce and acquisitions vital for enhancing competitive strength [7][8] - The industry is shifting from a low-competition, high-growth phase to a differentiated competition phase, necessitating continuous strategic adjustments from leading companies like Tian Tan Biological [8]